Antibiotic Susceptibility Testing

Standardizing the bacterial inoculum makes inhibition measurements comparable across tested antibiotics and isolates. The laboratory exposes that controlled bacterial population to selected drugs, then measures whether growth is inhibited. This consistency is essential because the resulting measurement must be interpreted against established breakpoints rather than viewed as an isolated observation from one culture.

Disk diffusion and broth dilution provide different testing formats within the same susceptibility framework. Both use a standardized inoculum and selected antibiotics, but the measured inhibition is used to estimate or interpret drug activity, with broth dilution specifically associated with determining a minimum inhibitory concentration. Comparing results across these formats requires consistent testing conditions and breakpoint interpretation.

Interpretive breakpoints convert a laboratory measurement into a clinically usable category: susceptible, intermediate, or resistant. This step matters because the raw extent of growth inhibition alone does not communicate how an isolate should be classified. Applying the breakpoint framework also makes results comparable for antimicrobial selection and for tracking resistance patterns across tested bacterial pathogens.

An isolate's laboratory profile must be considered alongside the patient's immune context. Susceptibility results identify drugs that inhibit the bacterial pathogen, while patients may have diverse immune responses that influence infection management. Thus, testing supplies microbiological guidance for treatment decisions without reducing the clinical situation to the growth measurement alone.

For an individual infection, the report helps narrow antimicrobial selection to drugs against which the bacterial isolate shows inhibition. That information is especially valuable when treatment must be managed in the setting of a diverse immune response, because clinicians can incorporate the laboratory profile into broader infection-management decisions.

At the population level, aggregated susceptibility results reveal resistance patterns rather than only the profile of one isolate. Those patterns can inform infection-control planning, antimicrobial-stewardship efforts, and surveillance for emerging resistance. In this way, testing generates information for managing antibiotic use and resistance trends as well as supporting current clinical decisions.